Search clinical trials for: Programmed death-ligand 1 (PD-L1)

Total 50099 results

Peking University People's Hospital

Unknown

PD-L1 Expression in Advanced Osteosarcoma

Progression | Survival

China
NYU Langone Health
EMD Serono

Completed

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Glioblastoma

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
The First People's Hospital of Lianyungang

Recruiting

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

Lung Neoplasms

China
Monika Joshi, MD
AstraZeneca

Active, not recruiting

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)

Urothelial Cancer

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Kiang Wu Hospital

Completed

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC)

Locally Advanced Cervical Cancer

France
National Cancer Institute (NCI)

Recruiting

Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Thymic Epithelial Tumor | Thymic Cancer | Recurrent Thymoma

United States
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Biotheus Inc.

Recruiting

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Soochow University
MITRO Biotech Co., Ltd.

Unknown

89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
King Faisal Specialist Hospital & Research Center
AstraZeneca

Completed

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Breast Cancer

Saudi Arabia
Diwakar Davar
Aculeus Therapeutics

Active, not recruiting

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NSCLC | Metastatic Colorectal Carcinoma | Refractory Melanoma

United States
Lei Li

Recruiting

Genetic Mutation in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1

China
Peking University Cancer Hospital & Institute

Recruiting

PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors

Solid Tumor

China
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer - EORTC; ETOP

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)

Non-small Cell Lung Cancer
Women's Hospital School Of Medicine Zhejiang University

Not yet recruiting

Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma

Cervical Cancer

China
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Melinta Therapeutics, Inc.

Completed

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Healthy

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Advanced Hepatocellular Carcinoma

China
Hunan Province Tumor Hospital

Recruiting

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.

Non-Small Cell Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Incyte Corporation

Recruiting

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable

United States
Western Sydney Local Health District
Bristol-Myers Squibb; University of Western Sydney

Recruiting

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (ICEMELT)

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Gastric Cancer | Mesothelioma | Endometrial Cancer | Lung Cancer, Nonsmall Cell

Australia
Groupe Hospitalier Pitie-Salpetriere

Recruiting

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors (JOCARDITE)

Heart Diseases | Cardiovascular Diseases | Vasculitis | Myocarditis | Cardiomyopathies | Pericarditis

France
Shadia Jalal, MD
AstraZeneca; MedImmune LLC; Big Ten Cancer Research Consortium

Completed

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Cancer, Solid Tumor
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
Xiaohua Zhu

Recruiting

PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer

NSCLC Stage IV | PD-L1 Gene Amplification

China
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Solid Tumor | Prostate Cancer | Advanced Solid Tumor | Metastatic Prostate Cancer | Prostate Neoplasm

United States
Changhai Hospital

Completed

Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis

Sepsis | Immunosuppression
Sichuan University
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

Small Cell Lung Cancer Extensive Stage
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
Agenus Inc.

Terminated

A Study in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
University of Erlangen-Nürnberg Medical School

Recruiting

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (ST-ICI02)

Renal Cell Carcinoma | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Squamous Cell Carcinoma of the Skin | Small Cell Bronchial Carcinomas

Germany
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Icahn School of Medicine at Mount Sinai

Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

Cancer | Thyroid | PD-1

United States
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
AstraZeneca

Active, not recruiting

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Non Small Cell Lung Carcinoma NSCLC

Poland, Taiwan, Thailand, Vietnam, United States, Korea, Republic of, Hungary, Russian Federation, Turkey, China, Australia, Netherlands
Olivia Newton-John Cancer Research Institute
Austin Health; Merck Healthcare KGaA

Terminated

Bioimaging Study of 89Zr-M7824 in NSCLC

Non-Small Cell Lung Cancer

Australia
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia

Search clinical trials for: Programmed death-ligand 1 (PD-L1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations